ストックスクリーナーアプリを入手
78.97
1.44%
1.12
アフターアワーズ：
79.22
0.25
+0.32%
前日終値:
$77.85
開ける：
$78.025
24時間の取引高:
11.64M
Relative Volume:
0.72
時価総額：
$199.22B
収益：
$64.17B
当期純損益:
$17.12B
株価収益率:
11.73
EPS:
6.73
ネットキャッシュフロー:
$18.10B
1週間 パフォーマンス:
+0.74%
1か月 パフォーマンス:
-15.19%
6か月 パフォーマンス:
-25.95%
1年 パフォーマンス:
-37.79%
1日の値動き範囲:
$77.66
$79.04
1週間の範囲:
$75.93
$79.04
52週間の値動き範囲:
$75.93
$134.63
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
78.97 | 199.22B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
827.54 | 743.27B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.75 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
173.78 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
59.91 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.41 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Merck Says Health Canada Approves Keytruda Combination Therapy for Pleural Mesothelioma - marketscreener.com
Animal Vaccines Market Detailed In New Research Report 2025 | - openPR.com
Lobbying Update: $1,800,000 of MERCK & CO INC lobbying was just disclosed - Nasdaq
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Benzinga
Merck & Co.: Pipeline Resilience To Unlock Value (NYSE:MRK) - Seeking Alpha
Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights - GlobeNewswire Inc.
Merck & Co., Inc.’s (MRK) “Buy” Rating Reiterated at Guggenheim - Defense World
Lobbying Update: $50,000 of MERCK & CO. INC. lobbying was just disclosed - Nasdaq
Merck & Co., Inc. (MRK): Among Value Stocks in Ken Fisher’s Portfolio - Insider Monkey
Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income - Yahoo Finance
Is Merck & Co., Inc. (MRK) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assessing Merck & Co: Insights From 9 Financial Analysts - Benzinga
Is Merck & Co., Inc. (MRK) The Dirt Cheap Stock To Invest In Now? - Yahoo Finance
BMO Capital Adjusts Merck Price Target to $89 From $96 - marketscreener.com
Leerink Partners Adjusts Price Target on Merck to $115 From $113, Keeps Outperform Rating - MarketScreener
Merck & Co., Inc. (MRK): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Yahoo Finance
Companion Animal Medicine Market Top PlayersMerck & Co., Inc.; - openPR.com
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Rep. Kelly Morrison Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Price Over Earnings Overview: Merck & Co - Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery - Benzinga
April 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRK - TradingView
Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock - Defense World
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Merck to Integrate Medical Resources Into Microsoft's Health Care AI Platform - MarketScreener
Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds? - Insider Monkey
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Business Wire
What to Expect From Merck & Co.'s Next Quarterly Earnings Report - TradingView
What To Expect From Merck & Co.'s Next Quarterly Earnings Report - Barchart.com
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires? - Insider Monkey
MRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
FINAL MRK DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Merck & Co., Inc. Investors to Join the Class Action Lawsuit - markets.businessinsider.com
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. - Bluefield Daily Telegraph
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Jim Cramer on Merck (MRK): Stay The Course… It’s Been a Real Tough One - Yahoo Finance
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
MRK Lawsuit Alert! Class Action Lawsuit Against Merck & Company - TipRanks
Investors who lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class ActionMRK - PR Newswire
Merck (MRK) Faces Shareholder Proposals Amid Market Challenges - GuruFocus
Merck (MRK) Poised for Growth with Strong Financial Performance - GuruFocus
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
0.79%
大文字化:
|
ボリューム (24 時間):